Results 141 to 150 of about 40,259 (213)

Osimertinib induces reversible cardiac dysfunction through the GATA4-MYLK3-MYL2 axis. [PDF]

Eur Heart J
Zhang K, Ayala A, Norambuena-Soto I, Agnihotri V, Shu T, Nenninger C, Wang Y, Echevarria B, Aboagye J, Huang K, Espitia-Corredor J, Wu X, Chen ZB, Deng Y, Perry JJP, Raz DJ, Yang H, Cheng P, Fu G, Wang ZV, Rhee JW.   +20 more
europepmc   +1 more source

Efficacy and safety of myosin inhibitors for symptomatic hypertrophic cardiomyopathy: systematic review and meta-analysis. [PDF]

Arch Med Sci Atheroscler Dis
Hazique M, Lohana S, Kafle S, Bhinder J, Patel KN, Basit J, Bahar AR, Kvapil J, Alraies MC.   +8 more
europepmc   +1 more source

Rho/ROCK Signaling Pathway in Kidney Diseases: Mechanisms and Therapeutic Perspectives. [PDF]

Biomedicines
Xiong W, Miao D, Hou Z, Zhang X, Xiong Z.   +4 more
europepmc   +1 more source

Coexistence of Hypertrophic Cardiomyopathy and Arterial Hypertension: Current Insights and Future Directions. [PDF]

Diseases
Katsi V, Papadomarkaki K, Manousiadis K, Triantafyllou E, Fragoulis C, Tsioufis K.   +5 more
europepmc   +1 more source

Cardiac Myosin Activators in Heart Failure: Experimental Advances Amid Clinical Uncertainty. [PDF]

Drug Des Devel Ther
Hou L, Lin B, Ji X, Huang A.
europepmc   +1 more source

Impact of Mavacamten Approval on Septal Reduction Therapy Rates in Hypertrophic Cardiomyopathy. [PDF]

J Am Heart Assoc
Ibrahim R, Wang W, Pham HN, Abdelnabi M, Lester SJ, Wilansky S, Schaff HV, Geske JB, Arsanjani R, Ayoub C.   +9 more
europepmc   +1 more source

Therapeutic Response to Myosin Inhibitor Therapy in Noonan Syndrome-Associated Obstructive Hypertrophic Cardiomyopathy. [PDF]

JACC Case Rep
Feidakis A, Nies R, Kural M, Pennig L, Winnerling N, Erger F, Pfister R, Seuthe K.   +7 more
europepmc   +1 more source

Advances in Non-Invasive Myocardial Stiffness Assessment and Clinical Applications in Hypertrophic Cardiomyopathy. [PDF]

Rev Cardiovasc Med
Gao Y, Qi N, Gao H, Deng Y, Liu Y.
europepmc   +1 more source

Emerging Pharmacological and Invasive Therapies for Hypertrophic Cardiomyopathy with Obstructive Physiology. [PDF]

Card Fail Rev
Li-Wen Chu E, Seung Kim D, Masri A.
europepmc   +1 more source

Mavacamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy During Active Chemotherapy. [PDF]

JACC Case Rep
Caro-Codón J, Valbuena-López S, Ghanem Cañete I, Pérez Wert JP, Refoyo E, Fernández García-Moya L, Saldaña-García J, Paños-Babin M, Moreno R, López-Fernández T.   +9 more
europepmc   +1 more source